A MedTech is launching to tackle obesity and associated cardiometabolic disorders after raising £334 million in Series A financing. Verdiva Bio, based in London, says it is developing a broad range of oral and injectable treatments to help with weight loss. Khurem Farooq, formerly the CEO of Aiolos Bio and Gyroscope Therapeutics, will serve as … Continue reading Obesity-fighting MedTech launches with £334m investment